Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00870623 · ClinicalTrials.gov registry record
Procalcitonin and Endotoxin Sequential Levels to Optimize the Treatment of Bloodstream Infections
A clinical trial, sponsored by University of Nebraska.
- Completed
- Registry status
- 223
- Enrollment target
NCT00870623 is a clinical trial that has completed, run by University of Nebraska. The registered enrollment target is 223 participants.
The verdict
NCT00870623 has completed, sponsored by University of Nebraska.
- COMPLETED
- Registry status
- 223 participants
- Enrollment target
Study Summary
Bloodstream infections (BSI) are a major cause of morbidity and mortality. Bloodstream infections are also costly and result in prolonged hospital stays. The duration of therapy necessary to clear blood stream infections is unknown and no study has systematically addressed this issue. However, the use of antimicrobials is not without consequence. These include financial cost, side-effects, promotion of superinfection (especially Clostridium difficile-associated diarrhea), and the promotion of microbial resistance. This study hypothesizes that a procalcitonin (host biomarker) and endotoxin (microorganism biomarker) guided treatment plan could significantly decrease unnecessary exposure to antibiotics in patients with bloodstream infections.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 223 participants |
| Start Date | 2009-06-01 |
| Est. Completion | 2016-01-13 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00870623
The ClinicalTrials.gov registry entry for NCT00870623 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 223 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Nebraska, which has 407 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 0 interventions.
NCT00870623 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00870623 about?
NCT00870623 is a clinical study titled "Procalcitonin and Endotoxin Sequential Levels to Optimize the Treatment of Bloodstream Infections". Bloodstream infections (BSI) are a major cause of morbidity and mortality. Bloodstream infections are also costly and result in prolonged hospital stays. The duration of therapy necessary to clear blood stream infections is unknown and no study has systematically addressed this issue. However, the u...
What is the current status of trial NCT00870623?
This trial is currently completed. The enrollment target is 223 participants. The study started on 2009-06-01. Estimated completion is 2016-01-13.
Who is sponsoring clinical trial NCT00870623?
This trial is sponsored by University of Nebraska, which has 407 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.